New   AI-assisted compliance for Indian businesses. Plan your India entry → ☎ +91-8595441494 contact@kamrit.com Login →

Business Plans › Pharma & Healthcare

Hospital (Multi-Specialty) (Small Scale) Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Report Format: PDF + Excel  |  Report ID: KMR-B3-2084  |  Pages: 176

Last reviewed: by KAMRIT research team

Article below is indicative only

This free report description below is to give you an investor-grade overview of the opportunity, CapEx range, regulatory architecture, and project economics. Specific BIS / IS standard numbers, FSSAI thresholds, licence fees, GST HSN codes, and government scheme rates change frequently and should be verified against the issuing authority before commitment. Engage KAMRIT for a verified, project-specific compliance map signed off by a named partner.

Market size, FY2026

₹41,055 crore

CAGR 2026-2033

13.3%

CapEx range

₹12.5 crore - ₹549 crore

Payback

3.2 - 6.1 yrs

Hospital (Multi-Specialty) (Small Scale): DPR Summary

India's healthcare infrastructure sector stands at an inflection point, with the multi-specialty hospital market projected to reach ₹41,055 crore in FY2026 and expand to ₹98,590 crore by 2033, reflecting a CAGR of 13.3 percent over the 2026-2033 horizon. This growth trajectory is underpinned by rising health insurance penetration, the escalating chronic disease burden, and targeted government support through the PLI Scheme for Bulk Drugs and Medical Devices. For a small-scale multi-specialty hospital project with a CapEx range of ₹12.5 crore to ₹549 crore, the market opportunity is compelling.

Established operators such as Dr. Lal PathLabs, Fortis Healthcare, and Max Healthcare command significant bed capacity and brand equity across urban corridors, creating both competitive density and a demonstrable demand signal. The projected payback of 3.2 to 6.1 years positions hospital infrastructure as a bankable asset class within India's healthcare buildout.

This report provides the strategic, regulatory, financial, and operational intelligence required to structure a bankable Detailed Project Report under the KAMRIT Financial Services LLP mandate for kamrit.com, covering sectoral positioning, technology selection, financing architecture, and risk mitigation frameworks.

PLI Bulk Drug and Medical Devices and US generics export opportunity make the Indian hospital (multi-specialty) (small scale) category one of the higher-growth slots in its parent industry (13.3% CAGR, ₹41,055 crore today). KAMRIT's bankable DPR for a mid-cap MSME plant arrives in 14 business days.

The report is positioned for a mid-cap MSME entrant and is structured for direct submission to a commercial bank or NBFC for term-loan sanction under the Means of Finance set out below.

Market trajectory

₹41,055 crore in 2026, projected ₹98,590 crore by 2033 at 13.3% CAGR.

0 cr 25,829 cr 51,658 cr 77,486 cr 1.03 lakh cr 2026: ₹41,055 cr 2027: ₹46,515 cr 2028: ₹52,702 cr 2029: ₹59,711 cr 2030: ₹67,653 cr 2031: ₹76,651 cr 2032: ₹86,845 cr 2033: ₹98,396 cr ₹98,396 cr 202620302033

Projection at constant CAGR; actual trajectory varies with macro and category shifts.

Regulatory and licence map for this hospital (multi-specialty) (small scale) project

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The licensing and approval architecture for a multi-specialty hospital in India is multi-layered, requiring sequential and parallel clearances from central and state authorities. The primary regulatory body is the State Health Department under the Clinical Establishments (Registration and Regulation) Act, 2010, where applicable, supplemented by Central Drugs Standard Control Organisation clearances for in-house pharmacy and radiopharmaceutical usage.

  • State Health Department Hospital Registration: Application to the respective State Health Authority (e.g., Delhi Nursing Home Registration Act or equivalent state statute) with site plan, staff qualifications, equipment list, and fire safety certificate. Fee varies by state; timelines range from 45 to 120 days for fresh registration and renewal every 3 to 5 years.
  • CDSCO Drug Licence (Form 20B/21B): Required under the Drugs and Cosmetics Act, 1940 and Rules 1945 for operating an in-house pharmacy dispensing Schedule H, H1, and X drugs. Form 20B for retail sale and Form 21B for loan licence arrangements. Compliance with Schedule M Good Manufacturing Practices is mandatory for any manufacturing activity within the hospital pharmacy.
  • Atomic Energy Regulatory Board (AERB) Licence: Mandatory for installation and operation of medical diagnostic X-ray equipment, CT scanners, linear accelerators, and mammography units. Application via AERB's online portal with shielding design certification from a qualified medical physicist. Licence validity is typically 5 years with annual fee renewal.
  • NABH Accreditation (National Accreditation Board for Hospitals and Healthcare Providers): While voluntary, NABH certification from Quality Council of India is increasingly mandated by insurance companies and CGHS for empanelment. The pre-assessment, documentation, and on-site assessment cycle spans 12 to 18 months. Insurance companies including United India Insurance, New India Assurance, and Oriental Insurance extend significantly higher reimbursement rates to NABH-accredited hospitals, directly impacting revenue per occupied bed.
  • Bio-Medical Waste Management Authorisation: Mandatory under the Bio-Medical Waste Management Rules, 2016 (as amended). Requires authorisation from the respective State Pollution Control Board. Segregation, storage, transport, and disposal through CBMWTF-authorised operators must be contracted before commissioning. Annual reporting to SPCBs and MoEFCC is compulsory.
  • NOC from State Pollution Control Board (Water and Air Acts): Consent to Establish and Consent to Operate under the Water (Prevention and Control of Pollution) Act, 1974 and Air (Prevention and Control of Control) Act, 1981. Applicable for hospitals with more than 50 beds or with STP and ETP installations. ETP sludge disposal must be tracked through manifest documents.
  • Parmacy Licence under Narcotic Drugs and Psychotropic Substances Act: Required if the hospital dispenses opioid analgesics such as morphine or fentanyl for palliative and surgical care. Separate Form NM-1 application to the State Drug Controller under NDPS Act, 1985 with storage security specifications.
  • GST Registration, EPF, and ESI Compliance: GST registration under GSTN for all taxable supplies. EPF registration for establishments with 20 or more employees under the EPF and Miscellaneous Provisions Act, 1952. ESI registration through the Employees' State Insurance Corporation for establishments with 10 or more employees in covered states. Both EPF and ESI certificates are scrutinised by lenders during term loan appraisal.

KAMRIT Financial Services LLP manages the complete end-to-end filing of all central and state regulatory approvals, including CDSCO licence coordination, AERB submission, NABH documentation support, and SPCB consent management. Our team interfaces directly with each authority, tracks timelines, and ensures post-filing compliance documentation is archived for lender due-diligence packs.

Compliance setup process

Typical sequence to take this project from incorporation to ready-to-operate. Phases overlap in practice; durations are working-day estimates with normal MCA / state portal turnaround.

Indicative timeline: ~3 to 6 months total PHASE 1 Entity formation 2-3 weeks hover for detail PHASE 2 CDSCO + Drug L... 8-16 weeks hover for detail PHASE 3 Factory & safety 4-8 weeks hover for detail PHASE 4 Environmental 6-16 weeks hover for detail PHASE 5 Tax & schemes 2-4 weeks hover for detail Phase 1 must complete before Phases 2-5. Phases 2-5 can largely run in parallel once entity is incorporated.
Sectoral context for this hospital (multi-specialty) (small scale) project

The multi-specialty hospital segment in India is differentiated from single-specialty and diagnostic chains by its capex intensity, staffing complexity, and cross-departmental revenue interdependence. Key sub-segments exhibiting differentiated growth rate gradients include tertiary cardiac care (growing at 15-16 percent CAGR driven by interventional procedure volumes), oncology services (16-18 percent CAGR with radiation therapy and DAYC centre demand), orthopaedics and joint replacement (12-14 percent CAGR correlating with India's aging population), maternal and neonatal care (11-13 percent CAGR in tier-2 and tier-3 cities), and diagnostic and pathology services (14-15 percent CAGR as standalone and in-house labs proliferate). Daycare and short-stay surgical centres are emerging as capital-efficient sub-segments within the multi-specialty fold, allowing smaller operators to achieve 65-75 percent bed occupancy faster than traditional multi-day admission models.

The Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana ecosystem continues to drive inpatient volumes in the ₹12.5 crore to ₹549 crore CapEx band, particularly in states such as Gujarat, Maharashtra, Karnataka, and Tamil Nadu, where state-sponsored top-up schemes layer additional reimbursement streams over AB PMJAY base rates. The competitive landscape is characterised by Fortis Healthcare's aggressive expansion through managed model hospitals, Max Healthcare's focus on quaternary care in metro catchments, and Apollo Hospitals' hub-and-spoke model anchoring regional clusters; these three operators collectively represent the benchmark for operating-cost structures that the project must benchmark against for credibility with lending institutions.

Project-specific demand drivers

  • PLI Bulk Drug and Medical Devices
  • US generics export opportunity
  • Health insurance penetration rising
  • Chronic disease burden growth
Demand drivers

Ordered by KAMRIT's view of relative importance for this category in India.

Top drivers (longer bar = stronger signal) PLI Bulk Drug and Medical Devices (relative weight ~100%) 1. PLI Bulk Drug and Medical Devices Relative weight ~100% US generics export opportunity (relative weight ~80%) 2. US generics export opportunity Relative weight ~80% Health insurance penetration rising (relative weight ~60%) 3. Health insurance penetration rising Relative weight ~60% Chronic disease burden growth (relative weight ~40%) 4. Chronic disease burden growth Relative weight ~40% Weights are KAMRIT's heuristic ordering, not empirical regression.
Technology and machinery benchmarks

For a multi-specialty hospital in the ₹12.5 crore to ₹549 crore CapEx band, technology selection must balance clinical capability with operating-cost sustainability. The core diagnostic stack typically comprises a 16-slice to 64-slice CT scanner (Siemens Somatom or GE Revolution series representing 60-65 percent of the installed base in Indian hospitals), a 1.5T MRI system (Canon Vantage or Philips Ingenia), digital radiography with flat panel detectors, and fully automated biochemistry and haematology analysers (Roche Cobas or Abbott Architect platforms). In-house laboratory automation can reduce per-test labour costs by 30-40 percent compared to manual processing, with turnaround time reductions from 4-6 hours to 90-120 minutes for routine panels.

For surgical services, a modular operation theatre suite with laminar airflow, HEPA filtration, and positive pressure ventilation is standard; each OT costs ₹75 lakh to ₹1.5 crore to commission including equipment, furnishings, and HVAC. ICU beds equipped with multi-parameter patient monitors, ventilators, and syringe pumps command a capital cost of ₹12 lakh to ₹18 lakh per bed. The hospital information management system (HIMS) is a non-negotiable investment; cloud-based platforms such as NaviMedix, Attune, or Tasy allow integration of LIS, radiology information system, and billing, reducing average billing cycle time from 5-7 days to 24-48 hours and improving working-capital efficiency.

Energy systems should incorporate VRF air-conditioning for patient rooms (30-35 percent lower energy cost versus split AC), solar rooftop installations supported by IREDA grid-connectivity norms, and LED lighting throughout, targeting an energy cost of ₹2.8 to ₹3.5 per KWh against the national average of ₹5.5 to ₹7 per KWh for hospital-grade comfort cooling. Medical gas pipeline systems with manifolded oxygen, vacuum, and compressed air represent ₹25 lakh to ₹60 lakh per 100-bed facility and must comply with IS 15050 and HTM 02-01 standards.

Bankable Means of Finance for this hospital (multi-specialty) (small scale) project

The recommended means of finance for a project in this CapEx band is a 70:30 debt-to-equity structure, calibrated to achieve a debt-service coverage ratio of 1.35 to 1.5 at 65 percent bed occupancy in the stabilisation year. For projects in the ₹12.5 crore to ₹100 crore range, SIDBI's Healthcare Sector Finance scheme offers term loans at rates of 8.5 to 10.5 percent with tenures up to 10 years, including a 2 percent interest subsidy under the Prime Minister's Employment Generation Programme for projects in Aspirational Districts. For the ₹100 crore to ₹549 crore band, a consortium led by State Bank of India Healthcare Finance or HDFC Bank Infrastructure Finance, with Axis Bank and ICICI Bank as co-lenders, provides the depth of credit and syndication capacity required; SBI's healthcare-specific product offers loan tenures of 12-15 years with step-down repayment structures aligned to the 3.2 to 6.1 year payback trajectory. Projects located in MIHAN (Nagpur), Pithampur (Madhya Pradesh), or Sriperumbudur (Tamil Nadu) may access state-level MSME incentive schemes including land at subsidised rates, electricity duty exemption for 5-7 years, and VAT refunds, materially improving the effective equity IRR by 150 to 250 basis points. Working-capital requirement is estimated at 25-30 percent of annual operating cost, covering a debtor cycle of 45-60 days under insurance reimbursement models and 15-20 days under out-of-pocket payment models. The blended working-capital cycle for a hospital with 60 percent insurance and 40 percent self-pay mix is approximately 52-58 days. Letter of Credit facilities for equipment imports (CT and MRI scanners sourced from Siemens or GE typically originate from Germany or the US) should be structured through EXIM Bank's export credit facilities to reduce the cost of capital by 50-100 basis points versus commercial LC pricing.

CapEx allocation (indicative)

Project CapEx ranges ₹12.5 crore - ₹549 crore. Typical split for a viable, bank-ready configuration:

Plant & machinery: 45% (approx. ₹126.3 cr of ₹280.8 cr CapEx) 45% Building & civil: 22% (approx. ₹61.8 cr of ₹280.8 cr CapEx) 22% Utilities & power: 12% (approx. ₹33.7 cr of ₹280.8 cr CapEx) 12% Working capital: 14% (approx. ₹39.3 cr of ₹280.8 cr CapEx) 14% Contingency & misc: 7% (approx. ₹19.7 cr of ₹280.8 cr CapEx) AVERAGE ₹280.8 cr CapEx Plant & machinery 45% · ~₹126.3 cr Building & civil 22% · ~₹61.8 cr Utilities & power 12% · ~₹33.7 cr Working capital 14% · ~₹39.3 cr Contingency & misc 7% · ~₹19.7 cr Low ₹12.5 cr High ₹549 cr

Split is a typical mid-cap manufacturing configuration. Actual allocation varies with site, automation level, and import vs domestic equipment sourcing.

Cumulative cash position

Cumulative free cash from ₹280.8 cr CapEx, indicative breakeven by Year 4-5 at conservative utilisation assumptions.

0 ₹168.5 cr ₹-393.05 cr Year 1: negative ₹-364.97 cr cumulative (this year cash flow ₹-84.22 cr) Year 1 Year 2: negative ₹-252.67 cr cumulative (this year cash flow +₹28.1 cr) Year 2 Year 3: negative ₹-154.41 cr cumulative (this year cash flow +₹98.3 cr) Year 3 Year 4: negative ₹-28.08 cr cumulative (this year cash flow +₹126.3 cr) Year 4 Year 5: positive +₹112.3 cr cumulative (this year cash flow +₹140.4 cr) Year 5

Model assumes 60% Year 1 utilisation, ramp to 90% by Year 3, 18% EBITDA on revenue ~1.6x CapEx at maturity. Engagement scope refines these to your specific configuration.

Risks and mitigation for this project

Three risks are material to the bankability of this project. First, regulatory and accreditation timeline risk: NABH accreditation requires 12-18 months of structured preparation, and empanelment with major insurance companies including HDFC ERGO, Bajaj Allianz, and Star Health is contingent on NABH certification. A delay of 6-9 months in achieving insurance empanelment directly compresses revenue-per-occupied-bed by 20-25 percent during the stabilisation phase, as patients default to cash payment or seek treatment at empanelled competitors.

The mitigation structure within the DPR must include a bridge financing facility of ₹1.5 crore to ₹3 crore to cover operating costs during the empanelment lag. Second, medical talent acquisition risk in tier-2 and tier-3 catchment areas is acute; specialist retention costs in cities such as Ahmedabad, Pune, Indore, and Coimbatore have escalated by 18-22 percent annually due to competition from large hospital chains. The sensitivity analysis should model a 15 percent increase in staffing cost as a downside scenario, which reduces DSCR from 1.42 to 1.18 at 60 percent occupancy.

Third, competitive response risk from established operators such as Fortis Healthcare and Max Healthcare entering the same catchment through managed-model or franchise-format hospitals creates pricing pressure on consultation fees and procedure tariffs. The DPR's competitive mitigation strategy should position the project on a 15-20 percent cost advantage over quaternary care competitors through lean OT scheduling, shared services with diagnostic chains, and lower per-bed real estate cost by situating in peri-urban corridors rather than city centres.

Risk matrix

Category-typical risks plotted by impact and probability. Hover a numbered dot to see the risk.

CDSCO approval delay: impact 3/3, probability 2/3 1 GMP audit findings: impact 3/3, probability 2/3 2 API price volatility: impact 2/3, probability 3/3 3 IPR / patent challenge: impact 3/3, probability 1/3 4 Distribution channel access: impact 2/3, probability 2/3 5 Probability → Impact → Low Medium High High Medium Low
1. CDSCO approval delay
2. GMP audit findings
3. API price volatility
4. IPR / patent challenge
5. Distribution channel access

How to engage with KAMRIT on this report

KAMRIT offers three engagement tiers tailored to the decision stage of the project. Pick the tier that matches what you actually need: pricing, scope, and turnaround are summarised in the sidebar.

Key market drivers

  • PLI Bulk Drug and Medical Devices
  • US generics export opportunity
  • Health insurance penetration rising
  • Chronic disease burden growth

Competitive landscape

The Indian hospital (multi-specialty) (small scale) market is sized at ₹41,055 crore in 2026 and is on a 13.3% trajectory to ₹98,590 crore by 2033. Apollo Hospitals, Fortis Healthcare and Manipal Hospitals hold the leading positions , with Max Healthcare, Narayana Health, Aster DM Healthcare, Medanta (Global Health) also profiled in this DPR. The full report benchmarks the new entrant's CapEx (₹12.5 crore - ₹549 crore) and unit economics against the listed-peer cost structure, identifies the specific competitive gap a 3.2 - 6.1-year-payback project can exploit, and includes channel-share and pricing-position analysis. Click any name to open its live profile, current stock price, and analyst note.

Apollo Hospitals Fortis Healthcare Manipal Hospitals Max Healthcare Narayana Health Aster DM Healthcare Medanta (Global Health)

What's inside the Hospital (Multi-Specialty) (Small Scale) DPR

The Hospital (Multi-Specialty) (Small Scale) DPR is a 176-page PDF (Tier 2 also ships an Excel financial model) built around a mid-cap MSME entrant assumption. It covers Schedule M-compliant layout, GMP cleanroom mapping, HVAC and WFI water system sizing, QA / QC lab design, validation protocols, and dossier preparation for CDSCO and export markets. The financial side runs the full project economics for ₹12.5 crore - ₹549 crore CapEx: line-itemised CapEx with vendor quotes, OpEx build-up by cost head, 5-year revenue projection by SKU and channel, P&L / balance sheet / cash flow, ROI, NPV, IRR, working-capital cycle, break-even, three-scenario sensitivity, and the Means of Finance recommendation. Payback of 3.2 - 6.1 years is back-tested against the listed-peer cost structure of Apollo Hospitals and Fortis Healthcare.

Numbers for this Hospital (Multi-Specialty) (Small Scale) project

Market, operating, and project economics at a glance

A focused view of the numbers that decide this mid-cap MSME project. The Bankable DPR breaks each of these down into the full state-by-state and vendor-by-vendor schedule.

India Multi-Specialty Hospital Market Size FY2026

₹41,055 crore

Market valuation at current year; forms the baseline for the 2026-2033 projection period.

Projected Market Size 2033

₹98,590 crore

Forecast market size at end of CAGR period; implies 2.4x expansion over 7 years.

CAGR 2026-2033

13.3%

Compound annual growth rate applied to the ₹41,055 crore base to reach ₹98,590 crore.

Project CapEx Range

₹12.5 crore to ₹549 crore

Project-specific investment band across small-scale to mid-scale hospital configurations.

Payback Period

3.2 to 6.1 years

Range reflects occupancy ramp-up, insurance empanelment, and specialty mix assumptions.

Target Bed Occupancy Year 2

65-70%

Occupancy rate benchmark for DSCR stress testing and lender covenant compliance.

Revenue per Occupied Bed per Day

₹4,500 to ₹8,500

Range reflects medical cases at lower end and surgical or ICU cases at upper end; blended average ₹6,200.

Energy Cost per KWh (with VRF and Solar)

₹2.8 to ₹3.5

Post-solar rooftop installation; versus ₹5.5 to ₹7 per KWh for conventional HVAC; 35-40% reduction in energy opex.

City-specific versions of this report

Setting up in your city? 20 location-specific overlays included.

Each city version of this report layers in state-specific subsidies, the local industrial land cost band, electricity tariff, distance to the nearest export port, and the closest state industrial policy headline: useful when shortlisting a location for your unit.

Table of Contents

20 chapters, 176 pages. Excel financial model included with Tier 2 and Tier 3.

Executive Summary 6 pages
Industry Overview & Market Size 14 pages
Demand & Supply Analysis 12 pages
Regulatory Framework & Licences 18 pages
Plant Setup & Location Strategy 14 pages
Manufacturing / Operating Process 16 pages
Raw Materials & Utilities 12 pages
Machinery & Equipment Specifications 18 pages
Manpower Plan & Organisation Structure 8 pages
Packaging, Branding & Distribution 10 pages
Project Cost (CapEx) & Means of Finance 14 pages
Operating Cost (OpEx) Build-Up 10 pages
Revenue Projections (5-year) 8 pages
Profitability & ROI Analysis 10 pages
Break-Even & Sensitivity Analysis 8 pages
Working Capital Requirements 6 pages
Environmental Clearance & Compliance 10 pages
Risk Assessment & Mitigation 6 pages
Competitive Landscape & Key Players 10 pages
Conclusion & Recommendations 5 pages

FAQs about this Hospital (Multi-Specialty) (Small Scale) project

What is the projected market size for India's multi-specialty hospital sector and what does this mean for a small-scale project?

India's multi-specialty hospital market is valued at ₹41,055 crore in FY2026 and is forecast to reach ₹98,590 crore by 2033, growing at a CAGR of 13.3 percent. For a project in the ₹12.5 crore to ₹549 crore CapEx band, this implies significant headroom for occupancy ramp-up, particularly in underserved tier-2 and tier-3 cities where the current bed density is 0.9 beds per 1,000 population against the WHO recommended 3.5.

What is the typical payback period for a small-scale multi-specialty hospital in India?

The project-specific payback range is 3.2 to 6.1 years, with the variation driven by bed occupancy ramp-up speed, insurance empanelment timelines, and the specialty mix. A hospital achieving 70 percent occupancy within 18 months of commissioning with NABH accreditation and empanelment with three or more insurance providers is expected to reach payback in the lower half of this range.

How does NABH accreditation impact revenue in a small-scale hospital?

NABH accreditation is a prerequisite for empanelment with major health insurers including United India Insurance, New India Assurance, and Star Health. NABH-accredited hospitals receive 15-20 percent higher reimbursement rates under insurance claims compared to non-accredited facilities, directly increasing revenue per occupied bed by ₹1,200 to ₹1,800 per day on average across surgical and medical cases.

What CapEx investment is required for a 50-bed to 100-bed multi-specialty hospital in this category?

The CapEx range for the project is ₹12.5 crore to ₹549 crore. For a 50-bed facility, capital investment typically ranges from ₹12.5 crore to ₹25 crore, covering civil construction at ₹3,500 to ₹5,500 per square foot, medical equipment at ₹4 crore to ₹7 crore, and commissioning costs including HIMS, medical gases, and OT fit-out at ₹1.5 crore to ₹3 crore.

Which lenders and financial institutions offer specialised products for hospital projects in India?

SBI Healthcare Finance, HDFC Bank Infrastructure Finance, Axis Bank Healthcare Loans, and SIDBI's Healthcare Sector Finance are the primary lenders. For projects in eligible clusters, SIDBI offers interest rate concessions of up to 2 percent under PMEGP. EXIM Bank's export credit facility is applicable for imported diagnostic equipment. State-level schemes in Gujarat, Maharashtra, and Karnataka offer additional subsidy layers for MSME-classified hospital projects.

What are the key operating benchmarks a lender will scrutinise in the DPR?

Lenders focus on bed occupancy rate (target 65-70 percent by year 2), average length of stay (3.2 to 4.5 days for multi-specialty), revenue per occupied bed per day (₹4,500 to ₹8,500 depending on specialty mix), debtor collection period (45-60 days under insurance models), and cost per bed per month (₹1.2 lakh to ₹2.0 lakh including staffing, utilities, and consumables). The DSCR must remain above 1.25 at the stress case of 55 percent occupancy.

Not sure which tier you need?

Senior Partner Vishal Ranjan or Associate Vidushi Kothari will take a 20-minute scoping call and recommend the right engagement tier for your decision stage. Response within one business day.